CHARLOTTE – Unable to secure funding to support its operations, Durham biotech Aceragen plans to liquidate its assets.
Aceragen is moving to transfer its assets to an assignee who will liquidate the assets for the benefit of the company’s creditors. The company’s stockholders need to approve the decision.
[Last September, Aceragen, launched in 2021 with a focus on rare illnesses and hopes to be the first to find a treatment for Farber disease, merged with a publicly held pharmaceutical firm Idera Pharmaceuticals in an all-stock deal.]
Related news
Durham biotech startup backed by NovaQuest merges with public pharma firm
